Back to Dashboard








Adaptive Biotechnologies Corpor (ADPT)
Real-time intraday values
Market Overview
From:
To:
ADPT Intraday
No data available
SymbolADPT
IPO DateJun 27, 2019
CEOMr. Chad M. Robins M.B.A.
Full Time Employees624
SectorHealthcare
IndustryDiagnostics & Research
CountryUnited States
ExchangeNasdaqGS
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Performance
| Period | Return % | Value Change |
|---|---|---|
| 1 Day | +1.20% | +0.21 US$ |
| 5 Days | -5.66% | -1.06 US$ |
| 1 Month | +37.72% | +4.84 US$ |
| 6 Months | +9.62% | +1.55 US$ |
Analyzing Market with AI
Evaluating the last 30 days of history and fundamental metrics of ADPT...
Key Statistics
Market Cap
2.83B
P/E Ratio
N/A
Div Yield
N/A
52W High
$20.76
52W Low
$9.96
Analyst Consensus
ConsensusStrong Buy
Bullish787.5%
Neutral112.5%
Bearish00.0%
52W Analyst Price Targets
Min Target
$18.00
$18.00
Max Target
$22.00
$22.00
Current$17.67
Avg Target$20.14
Analyst Recommendations
Target Price:$20.14($18.00 - $22.00)
Community Thoughts
Share your analysis and sentiment on ADPT
Join the community to share your analysis
Latest News for ADPT
Adaptive Biotechnologies Plans Offering of Senior Notes due 2031
MT Newswires•Jun 15, 2026, 08:25 PM
Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering
GlobeNewswire•Jun 15, 2026, 08:05 PM
Adaptive Biotechnologies Weighs Separation of Immune Medicine Unit; Shares Fall After Hours
MT Newswires•Jun 15, 2026, 08:43 PM
Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses
GlobeNewswire•Jun 15, 2026, 08:10 PM
What Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for Investors?
Motley Fool•Jun 14, 2026, 10:46 PM
Adaptive Biotechnologies (ADPT) Moves 9.7% Higher: Will This Strength Last?
Zacks•Jun 12, 2026, 09:44 AM
OpenFold Consortium Adds Eleven New Members as Momentum Builds for Open AI Infrastructure in Biology and Drug Discovery
Business Wire•Jun 9, 2026, 01:00 PM
Adaptive Biotech (ADPT) Reports 35% Revenue Growth Driven by Strong clonoSEQ Performance in Q1 2026
Insider Monkey•Jun 3, 2026, 06:00 PM
How The Adaptive Biotechnologies (ADPT) Narrative Is Shifting Around A US$20 Fair Value Anchor
Simply Wall St.•Jun 4, 2026, 11:10 AM
Adaptive Biotechnologies Highlights clonoSEQ Growth, 2026 Cash Flow Goal at Conference
MarketBeat•Jun 3, 2026, 10:04 PM